176 related articles for article (PubMed ID: 7578619)
1. The analytical and clinical performance of the new Boehringer Mannheim Enzymun-Test PSA assay for prostate-specific antigen.
Blijenberg BG; Eman I; Boevé ER; Mössner E; Uhl W
Eur J Clin Chem Clin Biochem; 1995 Jun; 33(6):383-92. PubMed ID: 7578619
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of the COBAS CORE Immunoassay for measuring prostate-specific antigen (PSA)--multi-centre study results. The PSA Study Group.
Schambeck CM
Eur J Clin Chem Clin Biochem; 1995 Aug; 33(8):541-7. PubMed ID: 8547440
[TBL] [Abstract][Full Text] [Related]
3. Total and free PSA: a methodical and clinical evaluation of five assays.
Reiter W; Stieber P; Schmeller N; Nagel D; Hofmann K; Fateh-Moghadam A
Anticancer Res; 1997; 17(6D):4759-65. PubMed ID: 9494603
[TBL] [Abstract][Full Text] [Related]
4. Analytical evaluation of the new Prostatus PSA Free/Total assay for prostate-specific antigen as part of a screening study for prostate cancer.
Blijenberg BG; Bangma CH; Kranse R; Eman I; Schröder FH
Eur J Clin Chem Clin Biochem; 1997 Feb; 35(2):111-4. PubMed ID: 9056753
[TBL] [Abstract][Full Text] [Related]
5. The clinical value of the Enzymun-Test for total and free PSA--a multicentre evaluation.
Reiter W
Anticancer Res; 1999; 19(6C):5559-62. PubMed ID: 10697616
[TBL] [Abstract][Full Text] [Related]
6. Multicentre evaluation of a new fully automated enzyme immunoassay for total prostate-specific antigen.
Blijenberg BG; Kessler AC; Uhl W
Eur J Clin Chem Clin Biochem; 1995 Dec; 33(12):965-73. PubMed ID: 8845430
[TBL] [Abstract][Full Text] [Related]
7. The importance of human glandular kallikrein and its correlation with different prostate specific antigen serum forms in the detection of prostate carcinoma.
Recker F; Kwiatkowski MK; Piironen T; Pettersson K; Lümmen G; Wernli M; Wiefelspütz J; Graber SF; Goepel M; Huber A; Tscholl R
Cancer; 1998 Dec; 83(12):2540-7. PubMed ID: 9874461
[TBL] [Abstract][Full Text] [Related]
8. Determination of the "reflex range" and appropriate cutpoints for percent free prostate-specific antigen in 413 men referred for prostatic evaluation using the AxSYM system.
Vashi AR; Wojno KJ; Henricks W; England BA; Vessella RL; Lange PH; Wright GL; Schellhammer PF; Weigand RA; Olson RM; Dowell BL; Borden KK; Oesterling JE
Urology; 1997 Jan; 49(1):19-27. PubMed ID: 9000179
[TBL] [Abstract][Full Text] [Related]
9. Preoperative serum prostate specific antigen levels between 2 and 22 ng./ml. correlate poorly with post-radical prostatectomy cancer morphology: prostate specific antigen cure rates appear constant between 2 and 9 ng./ml.
Stamey TA; Johnstone IM; McNeal JE; Lu AY; Yemoto CM
J Urol; 2002 Jan; 167(1):103-11. PubMed ID: 11743285
[TBL] [Abstract][Full Text] [Related]
10. Use of a new hypersensitive assay for the detection of prostate specific antigen in prostate cancer.
Arai Y; Onishi H; Oishi K; Takeuchi H; Yoshida O
Jpn J Clin Oncol; 1993 Apr; 23(2):110-5. PubMed ID: 7685834
[TBL] [Abstract][Full Text] [Related]
11. Detection of prostate cancer relapse with prostate specific antigen monitoring at levels of 0.001 to 0.1 microG./L.
Yu H; Diamandis EP; Wong PY; Nam R; Trachtenberg J
J Urol; 1997 Mar; 157(3):913-8. PubMed ID: 9072598
[TBL] [Abstract][Full Text] [Related]
12. [Clinical evaluation of a new kit (IMX PA Dainapack) for detection of serum prostate specific antigen].
Machida T; Ohishi Y; Wada T; Akimoto S; Shimazaki J; Oda H; Yokoyama M; Tsukada T; Nakayama T; Akiyama A
Hinyokika Kiyo; 1993 Oct; 39(10):977-84. PubMed ID: 7505519
[TBL] [Abstract][Full Text] [Related]
13. Sensitive prostate specific antigen measurements identify men with long disease-free intervals and differentiate aggressive from indolent cancer recurrences within 2 years after radical prostatectomy.
Witherspoon LR; Lapeyrolerie T
J Urol; 1997 Apr; 157(4):1322-8. PubMed ID: 9120931
[TBL] [Abstract][Full Text] [Related]
14. Reverse transcriptase polymerase chain reaction for prostate specific antigen in the management of prostate cancer.
Gomella LG; Raj GV; Moreno JG
J Urol; 1997 Aug; 158(2):326-37. PubMed ID: 9224297
[TBL] [Abstract][Full Text] [Related]
15. First clinical results with Enzymun-Test for free PSA.
Gilson G; Lamy S; Humbel RL
Anticancer Res; 1997; 17(4B):2861-4. PubMed ID: 9329548
[TBL] [Abstract][Full Text] [Related]
16. Ultrasensitive detection of prostate specific antigen in the followup of 422 patients after radical prostatectomy.
Haese A; Huland E; Graefen M; Hammerer P; Noldus J; Huland H
J Urol; 1999 Apr; 161(4):1206-11. PubMed ID: 10081870
[TBL] [Abstract][Full Text] [Related]
17. Critical aspects related to the interpretation of the free-to-total PSA-ratio.
Wolff JM; Stocker G; Borchers H; Haubeck H; Greiling H; Jakse G
Anticancer Res; 1999; 19(4A):2633-6. PubMed ID: 10470208
[TBL] [Abstract][Full Text] [Related]
18. Insulin-like growth factor-binding protein-2 in patients with prostate carcinoma and benign prostatic hyperplasia.
Ho PJ; Baxter RC
Clin Endocrinol (Oxf); 1997 Mar; 46(3):333-42. PubMed ID: 9156044
[TBL] [Abstract][Full Text] [Related]
19. Early detection of recurrent prostate cancer with an ultrasensitive chemiluminescent prostate-specific antigen assay.
Ellis WJ; Vessella RL; Noteboom JL; Lange PH; Wolfert RL; Rittenhouse HG
Urology; 1997 Oct; 50(4):573-9. PubMed ID: 9338734
[TBL] [Abstract][Full Text] [Related]
20. The biologic lower detection limit of six ultrasensitive PSA assays.
Junker R; Brandt B; Semjonow A; Erren M; Zechel C; Assmann G
Anticancer Res; 1999; 19(4A):2625-8. PubMed ID: 10470206
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
